LAUSR

BACKGROUND Since the results of previous studies regarding the safety and efficacy of miglustat in GM2 gangliosidosis (GM2g) were inconsistent, we aimed to assess the miglustat therapy in GM2g patients. METHODS This study followed the latest version of PRISMA. We included the observational or interventional studies reporting GM2g patients under miglustat therapy by searching PubMed, Web of Science, and Scopus. Data extracted included the natural history of individual patient data, as well as the safety and efficacy of miglustat in GM2g patients. The quality assessment was performed using the Joanna Briggs Institute critical appraisal checklist. RESULTS A total of 1023 records were identified and reduced to 621 after removing duplicates. After screening and applying the eligibility criteria, 10 articles and 2 abstracts met the inclusion criteria. Overall, the studies represented 54 patients with GM2g under treatment of miglustat and 22 patients with GM2g in the control group. Among patients with available data 14 and 54 have been diagnosed with Sandhoff disease (SD) and Tay-Saches disease (TSD), respectively. Patients included in this review consisted of 23 infantile, 4 late-infantile, 18 juveniles, and 31 adult-onset GM2g. CONCLUSION Although miglustat should not be considered a definite treatment for GM2g, it seems that patients particularly those with infantile or late-infantile GM2g could benefit from miglustat therapy to some extent. We also suggested some hints for future studies to present their findings in a standard method to make it more possible to pool the available data in such rare diseases for a more comprehensive conclusion.